79 related articles for article (PubMed ID: 26945968)
1. The anti-proliferative effects of type I IFN involve STAT6-mediated regulation of SP1 and BCL6.
Hsu YA; Huang CC; Kung YJ; Lin HJ; Chang CY; Lee KR; Wan L
Cancer Lett; 2016 Jun; 375(2):303-312. PubMed ID: 26945968
[TBL] [Abstract][Full Text] [Related]
2. Counter-regulation mechanism of IL-4 and IFN-α signal transduction through cytosolic retention of the pY-STAT6:pY-STAT2:p48 complex.
Kim SH; Lee CE
Eur J Immunol; 2011 Feb; 41(2):461-72. PubMed ID: 21268015
[TBL] [Abstract][Full Text] [Related]
3. IFN-alpha activates Stat6 and leads to the formation of Stat2:Stat6 complexes in B cells.
Gupta S; Jiang M; Pernis AB
J Immunol; 1999 Oct; 163(7):3834-41. PubMed ID: 10490982
[TBL] [Abstract][Full Text] [Related]
4. Interferon-resistant Daudi cell line with a Stat2 defect is resistant to apoptosis induced by chemotherapeutic agents.
Du Z; Fan M; Kim JG; Eckerle D; Lothstein L; Wei L; Pfeffer LM
J Biol Chem; 2009 Oct; 284(41):27808-27815. PubMed ID: 19687011
[TBL] [Abstract][Full Text] [Related]
5. Bi-phasic effect of interferon (IFN)-alpha: IFN-alpha up- and down-regulates interleukin-4 signaling in human T cells.
Eriksen KW; Sommer VH; Woetmann A; Rasmussen AB; Brender C; Svejgaard A; Skov S; Geisler C; Ødum N
J Biol Chem; 2004 Jan; 279(1):169-76. PubMed ID: 14559900
[TBL] [Abstract][Full Text] [Related]
6. STAT6-mediated BCL6 repression in primary mediastinal B-cell lymphoma (PMBL).
Ritz O; Rommel K; Dorsch K; Kelsch E; Melzner J; Buck M; Leroy K; Papadopoulou V; Wagner S; Marienfeld R; Brüderlein S; Lennerz JK; Möller P
Oncotarget; 2013 Jul; 4(7):1093-102. PubMed ID: 23852366
[TBL] [Abstract][Full Text] [Related]
7. Global changes in STAT target selection and transcription regulation upon interferon treatments.
Hartman SE; Bertone P; Nath AK; Royce TE; Gerstein M; Weissman S; Snyder M
Genes Dev; 2005 Dec; 19(24):2953-68. PubMed ID: 16319195
[TBL] [Abstract][Full Text] [Related]
8. Interferon-gamma inhibits interferon-alpha signalling in hepatic cells: evidence for the involvement of STAT1 induction and hyperexpression of STAT1 in chronic hepatitis C.
Radaeva S; Jaruga B; Kim WH; Heller T; Liang TJ; Gao B
Biochem J; 2004 Apr; 379(Pt 1):199-208. PubMed ID: 14690454
[TBL] [Abstract][Full Text] [Related]
9. Type I IFN induced IL1-Ra expression in hepatocytes is mediated by activating STAT6 through the formation of STAT2: STAT6 heterodimer.
Wan L; Lin CW; Lin YJ; Sheu JJ; Chen BH; Liao CC; Tsai Y; Lin WY; Lai CH; Tsai FJ
J Cell Mol Med; 2008 Jun; 12(3):876-88. PubMed ID: 18494930
[TBL] [Abstract][Full Text] [Related]
10. Control of the STAT6-BCL6 antagonism by SWAP-70 determines IgE production.
Audzevich T; Pearce G; Breucha M; Günal G; Jessberger R
J Immunol; 2013 May; 190(10):4946-55. PubMed ID: 23589612
[TBL] [Abstract][Full Text] [Related]
11. Stat1 and Stat2 but not Stat3 arbitrate contradictory growth signals elicited by alpha/beta interferon in T lymphocytes.
Gimeno R; Lee CK; Schindler C; Levy DE
Mol Cell Biol; 2005 Jul; 25(13):5456-65. PubMed ID: 15964802
[TBL] [Abstract][Full Text] [Related]
12. Role of ISGF3 in modulating the anti-hepatitis B virus activity of interferon-alpha in vitro.
Zhang Q; Wang Y; Wei L; Jiang D; Wang JH; Rao HY; Zhu L; Chen H; Fei R; Cong X
J Gastroenterol Hepatol; 2008 Nov; 23(11):1747-61. PubMed ID: 17559358
[TBL] [Abstract][Full Text] [Related]
13. [An experimental study on antiviral effects of IFN alpha].
Lu NF; Huang AL; Tang N; Zheng RQ; Lin H; Zhu YB; Wu Y; Tao P
Zhonghua Gan Zang Bing Za Zhi; 2005 Dec; 13(12):892-6. PubMed ID: 16381632
[TBL] [Abstract][Full Text] [Related]
14. Reduction in p48-ISGFgamma levels confers resistance to interferon-alpha2a in MHCC97 cells.
Wu WZ; Sun HC; Gao YQ; Li Y; Wang L; Zhou K; Liu KD; Iliakis G; Tang ZY
Oncology; 2004; 67(5-6):428-40. PubMed ID: 15714000
[TBL] [Abstract][Full Text] [Related]
15. Interferon-gamma inhibits STAT6 signal transduction and gene expression in human airway epithelial cells.
Heller NM; Matsukura S; Georas SN; Boothby MR; Rothman PB; Stellato C; Schleimer RP
Am J Respir Cell Mol Biol; 2004 Nov; 31(5):573-82. PubMed ID: 15297269
[TBL] [Abstract][Full Text] [Related]
16. Paired Stat6 C-terminal transcription activation domains required both for inhibition of an IFN-responsive promoter and trans-activation.
Goenka S; Youn J; Dzurek LM; Schindler U; Yu-Lee LY; Boothby M
J Immunol; 1999 Nov; 163(9):4663-72. PubMed ID: 10528163
[TBL] [Abstract][Full Text] [Related]
17. Luteolin sensitizes the antiproliferative effect of interferon α/β by activation of Janus kinase/signal transducer and activator of transcription pathway signaling through protein kinase A-mediated inhibition of protein tyrosine phosphatase SHP-2 in cancer cells.
Tai Z; Lin Y; He Y; Huang J; Guo J; Yang L; Zhang G; Wang F
Cell Signal; 2014 Mar; 26(3):619-28. PubMed ID: 24333668
[TBL] [Abstract][Full Text] [Related]
18. IFN-gamma priming up-regulates IFN-stimulated gene factor 3 (ISGF3) components, augmenting responsiveness of IFN-resistant melanoma cells to type I IFNs.
Wong LH; Hatzinisiriou I; Devenish RJ; Ralph SJ
J Immunol; 1998 Jun; 160(11):5475-84. PubMed ID: 9605150
[TBL] [Abstract][Full Text] [Related]
19. The Tumor Suppressive Effects of HPP1 Are Mediated Through JAK-STAT-Interferon Signaling Pathways.
Hernandez JM; Elahi A; Clark W; Humphries LA; Wang J; Achille A; Seto E; Shibata D
DNA Cell Biol; 2015 Aug; 34(8):541-9. PubMed ID: 26061044
[TBL] [Abstract][Full Text] [Related]
20. Interferon-inducible Stat2 activation of JUND and CLDN4: mediators of IFN responses.
Jia D; Rahbar R; Fish EN
J Interferon Cytokine Res; 2007 Jul; 27(7):559-65. PubMed ID: 17651017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
